About Nanovery
Nanovery is a company based in London (United Kingdom) founded in 2018 by Jurek Kozyra. Nanovery has raised $2.12 million across 5 funding rounds from investors including Gov.uk, European Commission and UK Research and Innovation. The company has 1 employees as of November 30, 2020. Nanovery offers products and services including ASO Bioanalysis, siRNA Bioanalysis, Custom Assay Development, microRNA Biomarkers, and miRometer-122™ Technology. Nanovery operates in a competitive market with competitors including Scholar Rock, Fluxion Biosciences, Ionpath, SamanTree Medical and Phase Focus, among others.
- Headquarter London, United Kingdom
- Employees 1 as on 30 Nov, 2020
- Founders Jurek Kozyra
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nanovery Limited
- Date of Incorporation 26 Nov, 2018
- Jurisdiction NEWCASTLE UPON TYNE, TYNE AND WEAR, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.12 M (USD)
in 5 rounds
-
Latest Funding Round
Not available
-
Investors
Gov.uk
& 8 more
-
Employee Count
1
as on Nov 30, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nanovery
Nanovery offers a comprehensive portfolio of products and services, including ASO Bioanalysis, siRNA Bioanalysis, Custom Assay Development, microRNA Biomarkers, and miRometer-122™ Technology.
Service for analyzing antisense oligonucleotides in samples.
Quantifies small interfering RNA for research applications.
Creates tailored assays for nucleic acid detection needs.
Identifies and analyzes microRNA for diagnostic purposes.
Provides precise quantification of specific microRNA biomarkers.
People of Nanovery
Unlock access to complete
Unlock access to complete
Funding Insights of Nanovery
Nanovery has successfully raised a total of $2.12M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nanovery
Nanovery has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Gov.uk, European Commission and UK Research and Innovation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment finance is provided to small and medium-sized enterprises.
|
Locked | Locked | Locked | |
|
Early-stage investments are made in UK companies across diverse sectors.
|
Locked | Locked | Locked | |
|
Investments in early-stage tech startups are made by Earlymarket.
|
Locked | Locked | Locked |
Investor details for Nanovery
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nanovery
Investment portfolio details for Nanovery
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nanovery
Detailed financials for Nanovery
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nanovery Comparisons
Peer comparison for Nanovery
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nanovery
Nanovery operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Scholar Rock, Fluxion Biosciences, Ionpath, SamanTree Medical and Phase Focus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-based drugs for primary myopathies are developed and targeted.
|
|
| Locked | Locked | Locked |
Microfluidics-based tools for cellular analysis are provided.
|
|
| Locked | Locked | Locked |
Multiplexed ion beam imaging platform for tissue biopsies is developed.
|
|
| Locked | Locked | Locked |
A surgical digital microscope for tumor resection is developed.
|
|
| Locked | Locked | Locked |
Provider of virtual lens that generates High definition images without high-quality lenses
|
|
| Locked | Locked | Locked |
Solutions for image-guided interventional procedures are developed.
|
Detailed competitors of Nanovery
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nanovery
Complete news archive for Nanovery
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nanovery
Nanovery was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Nanovery is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Nanovery is a funded company, having raised a total of $2.12M across 5 funding rounds to date.
As of Nov 30, 2020, the latest employee count at Nanovery is 1.
Nanovery was founded in 2018 and is based in London, United Kingdom. Operations focus on the biotechnology sector, where nanotechnology and artificial intelligence are combined to create diagnostic tools. Nanobots are designed for injection into the bloodstream, enabling detection of specific cancer cell mutations. Upon identification, the nanobots illuminate the affected areas to aid in early diagnosis. The approach targets improvements in cancer detection accuracy.
Nanovery's top competitors include Scholar Rock, Ionpath and SamanTree Medical.
Nanovery offers ASO Bioanalysis, siRNA Bioanalysis, Custom Assay Development, microRNA Biomarkers, and miRometer-122™ Technology.
Nanovery has 9 investors. Key investors include Gov.uk, European Commission, UK Research and Innovation, European Union, and North East Fund.